FXI

Crude And Gold Trade Higher; Major Asia Indexes And Europe Rise - Global Markets Today While US Slept

Asia markets mixed as BOJ holds rates; focus on US PCE inflation data

Asia markets mixed as BOJ holds rates; focus on US PCE inflation data. Japan's yen hits weakest level in three decades as BOj keeps interest rate unchanged. Shanghai Composite extends winning streak to a third day. Investors now shifting focus to China's PMI data scheduled for release.

U.S. Treasury's Yellen Says 'China Shock' Was A Huge Loss Of Manufacturing Jobs In Parts Of U.S. That Have Not Recovered; Parts Of The U.S. Have Really 'Been Left Behind'; Free Trade Has To Be Something That Benefits People Throughout The Country; We Would Be Prepared To Use Authority To Sanction Chinese Banks If Necessary

U.S. Treasury's Yellen Says Consumer Spending In China Is 'Incredibly Low'; China Exporting Its Way To Full Employment Is Not Acceptable To The Rest Of The World; U.S. Experienced China Shock After China's Exports Surged To The U.S. Following Its Admittance To WTO

U.S. Treasury's Yellen Says We're Concerned About Overdependence On One Country For Total Global Supply Of This Range Of Products; China Has Agreed To Extended, Intense Discussion On The Issue; Overcapacity Issue Developed Over Many Years, It's Not Going To Be Solved In A Day Or A Week; Not Taking Anything Off The Table In Terms Of U.S. Response

U.S. Treasury's Yellen Says overcapacity In China Is Not Just A U.S. Issue, It's An Issue For Europe, Japan And Emerging Markets Like India And Mexico; We Have No Problem With China Producing And Selling Globally; U.S., Europe, Other Countries Want The Ability To Produce Clean Energy Goods

U.S. Treasury's Yellen Says China Has Acknowledged A Problem With Overcapacity; Emphasizing Undesirable Spillovers From Chinese Overcapacity

Apollomics Announces Approval Of Vebreltinib In China As A First-In-Class Treatment For Gliomas With MET Fusion Gene

Apollomics' partner in China, Avistone, received approval from National Medical Products Administration of China to expand the use of vebreltinib to the treatment of gliomas with PTPRZ1-MET fusion gene Approval based on results from a randomized Phase 2/3 trial. Vebrelinib is the world's first c-Met inhibitor approved for treatment of a glioma with the ZM fusion gene.